AT-1015

AT-1015 is a selective and orally active 5-HT2A serotonin receptor antagonist. AT-1015 exhibits antithrombotic effect. AT-1015 prolongs the time needed to occlusion of the artery with thrombus. AT-1015 impairs platelet aggregation and vasoconstriction[1][2].

Product Specifications

CAS Number

[190508-48-6]

UNSPSC

12352005

Target

5-HT Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=C(C1CCN(C=O)CC1)NCCN2CC/C(CC2)=C3C4=CC=CC=C4C=CC5=CC=CC=C/35.O.Cl

Molecular Formula

C29H36ClN3O3

Molecular Weight

510.07

References & Citations

[1]Hiatt, W. R., et al., (2004) . Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vascular medicine (London, England), 9 (1), 18-25. |[2]Kihara, H., et al., (2001) . Antithrombotic activity of AT-1015, a potent 5-HT (2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. European journal of pharmacology, 433 (2-3), 157-162.